공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 호흡기 세포융합 바이러스 치료제 시장(2016-2020년)

Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2016년 12월 상품 코드 409502
페이지 정보 영문 74 Pages
가격
US $ 2,500 ₩ 2,804,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,365,000 PDF (5-user license) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,486,000 PDF (Enterprise license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,730,000 PDF (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 호흡기 세포융합 바이러스 치료제 시장(2016-2020년) Global Human Respiratory Syncytial Virus Drugs Market 2016-2020
발행일 : 2016년 12월 페이지 정보 : 영문 74 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 호흡기 세포융합 바이러스 치료제 시장은 2016-2020년간 4.27%의 연평균 성장률(CAGR)로 성장할 전망입니다.

세계의 호흡기 세포융합 바이러스(Human Respiratory Syncytial Virus) 치료제 시장을 조사했으며, 시장 개요, 주요 제품 사례, 질환 개요, 파이프라인 동향, 시장 환경, 약제 카테고리별 동향, 지역별 매출 규모 추이와 예측, 시장 성장 영향요인 분석, 경쟁 환경, 주요 벤더 프로파일 등을 정리하여 전해드립니다.

제1장 주요 요약

제2장 조사 범위

  • 시장 개요
  • 주요 벤더의 제공 제품

제3장 시장 조사 방법

제4장 서론

제5장 질환 개요

  • 질환에 대해
  • 증상
  • 원인
  • 위험요인
  • 합병증
  • 검사 및 진단
  • 주요 구매 기준

제6장 파이프라인 분석

제7장 시장 환경

  • 세계의 호흡기 세포융합 바이러스 치료제 시장
  • Five Forces 분석

제8장 시장 분석 : 약제 카테고리별

  • 승인 의약품
  • 오프라벨 의약품

제9장 지역 분석

  • 미국
  • 유럽
  • 기타 지역

제10장 시장 성장 촉진요인

  • 대규모 환자 풀의 존재가 시장 성장을 가속
  • 새로운 제품의 시장 투입
  • 새로운 진단 툴이 환자 인구를 확대

제11장 성장 촉진요인의 영향

제12장 시장이 해결해야 할 과제

  • 의료기관 가이드라인 연속적 변경의 시장 성장에 대한 영향
  • 시장 기회의 장벽이 되는 시장의 순환적 성질
  • 시장에서의 한정적인 약제 가용성이 낮은 보급률을 유도

제13장 성장 촉진요인 및 과제의 영향

제14장 시장 동향

  • 새로운 참여 사업자의 시장 역학 변화 가능성
  • 전략적 제휴에 의한 혁신 강화
  • 신흥경제권의 적극적 R&D 참여

제15장 벤더 환경

  • 경쟁 시나리오

제16장 주요 벤더 분석

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
  • 그 외 주목을 끄는 벤더

제17장 부록

제18장 Technavio 소개

LSH 17.01.04

About Human Respiratory Syncytial Virus Drugs

Respiratory syncytial virus (RSV) is a virus that leads to infections in the lungs and the respiratory tract. It commonly affects most children in the ages 2 or below. RSV can also infect adults. In adults and the older population, the symptoms of RSV are mild and similar to that of common cold. Infection with RSV can be severe in certain cases, particularly in premature infants and babies with underlying health conditions. RSV can also become serious in the older population or adults with heart and lung diseases, or any individual with a very weak immune system.

Technavio's analysts forecast the global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global human respiratory syncytial virus drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.

The market is divided into the following segments based on geography:

  • Europe
  • ROW
  • US

Technavio's report, Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical

Other Prominent Vendors

  • Ablynx
  • ADMA Biologics
  • Alnylam Pharmaceuticals
  • Ark Biosciences
  • Aviragen Therapeutics
  • Bavarian Nordic
  • Boehringer Ingelheim
  • Gilead Sciences
  • ImmunoVaccine Technologies
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Medivir
  • Mucosis
  • Mymetics Corporation
  • Novavax
  • Regeneron Pharmaceuticals
  • ReViral
  • Vaxart

Market driver

  • Novel diagnostic tools increase patient population.
  • For a full, detailed list, view our report

Market challenge

  • Continuous change in guidelines from healthcare organizations impacts market growth.
  • For a full, detailed list, view our report

Market trend

  • Emergence of new entrants likely to change market dynamics.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our procurement specialist's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Symptoms
  • Causes
  • Risk factors
  • Complications
  • Tests and diagnosis
  • Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

  • Global respiratory syncytial virus drugs market
  • Five forces analysis

PART 08: Market segmentation by category of drug

  • Approved Drugs
  • Off-label drugs

PART 09: Geographical segmentation

  • Human respiratory syncytial virus drugs market in US
  • Human respiratory syncytial virus drugs market in Europe
  • Human respiratory syncytial virus drugs market in ROW

PART 10: Market drivers

  • Presence of large patient pool fuels market growth
  • Launch of novel products
  • Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges

  • Continuous change in guidelines from healthcare organizations impacts market growth
  • Cyclical nature of market hinders growth opportunities
  • Limited drugs in market leading to low penetration rates

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Emergence of new entrants likely to change market dynamics
  • Growing strategic collaborations fostering innovation
  • Active participation from emerging economies toward R&D

PART 15: Vendor landscape

  • Competitive scenario

PART 16: Key vendor analysis

  • AstraZeneca
  • AbbVie
  • GSK
  • Teva Pharmaceutical
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key customer segments of global human respiratory syncytial virus drugs market
  • Exhibit 03: Snapshot of RSV infection
  • Exhibit 04: Key buying criteria for RSV drugs
  • Exhibit 05: Factors affecting the adoption rates of RSV drugs
  • Exhibit 06: Pipeline analysis of key vendors in global human respiratory syncytial virus drugs market
  • Exhibit 07: Percentage share of drug candidates by stage of development
  • Exhibit 08: Pipeline candidates: Global human respiratory syncytial virus drugs market
  • Exhibit 09: Global human respiratory syncytial virus drugs market snapshot
  • Exhibit 10: Analysis of global human respiratory syncytial drugs market
  • Exhibit 11: Global human respiratory syncytial virus drugs market 2015-2020 ($ billions)
  • Exhibit 12: Emerging vendors and their initiatives
  • Exhibit 13: Opportunity analysis of global respiratory syncytial virus drugs market
  • Exhibit 14: Opportunity analysis in developed and emerging markets
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of global human respiratory syncytial virus drugs market by type of drug 2015
  • Exhibit 17: Segmentation of global human respiratory syncytial virus drugs market based on geography 2015 and 2020
  • Exhibit 18: Global human respiratory syncytial virus drugs market revenue by geography 2015-2020 ($ millions)
  • Exhibit 19: Incidence of RSV infections in US (on average every year)
  • Exhibit 20: Global human respiratory syncytial virus drugs market in US 2015-2020 ($ millions)
  • Exhibit 21: Key drivers and challenges in US
  • Exhibit 22: Human respiratory syncytial virus drugs market in Europe 2015-2020 ($ millions)
  • Exhibit 23: Trends in global human respiratory syncytial drugs market in Europe
  • Exhibit 24: Global human respiratory syncytial virus drugs market in ROW 2015-2020 ($ millions)
  • Exhibit 25: Key drivers and challenges in ROW
  • Exhibit 26: Trends in RSV epidemics
  • Exhibit 27: Potential products
  • Exhibit 28: Impact of drivers
  • Exhibit 29: Change in guidelines of AAPCID and its consequences
  • Exhibit 30: Impact of cyclical nature of RSV epidemics
  • Exhibit 31: Factors affecting penetration rates
  • Exhibit 32: Forcefield analysis of drivers and challenges in global human respiratory syncytial virus drugs market
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Potential entrants
  • Exhibit 35: Strategic alliances
  • Exhibit 36: Competitive structure analysis of global human respiratory syncytial virus drugs market 2015
  • Exhibit 37: Market share analysis 2015
  • Exhibit 38: Market penetration of various RSV drug manufacturers in global human respiratory syncytial virus drugs market (2015)
  • Exhibit 39: Strategic success factors of companies in global human respiratory syncytial virus drugs market
  • Exhibit 40: AstraZeneca: Key highlights
  • Exhibit 41: AstraZeneca: Strength assessment
  • Exhibit 42: AstraZeneca: Strategy assessment
  • Exhibit 43: AstraZeneca: Opportunity assessment
  • Exhibit 44: AstraZeneca: Revenue of Synagis 2013-2015 ($ billions)
  • Exhibit 45: AstraZeneca: Geographic segmentation of Synagis 2015
  • Exhibit 46: AbbVie: Strength assessment
  • Exhibit 47: AbbVie: Strategy assessment
  • Exhibit 48: AbbVie: Opportunity assessment
  • Exhibit 49: AbbVie: Revenue of Synagis 2013-2015 ($ millions)
  • Exhibit 50: GSK: Profile
  • Exhibit 51: GSK: Strength assessment
  • Exhibit 52: GSK: Strategy assessment
  • Exhibit 53: GSK: Opportunity assessment
  • Exhibit 54: GSK: Revenue of Ventolin 2013-2015 ($ billions)
  • Exhibit 55: GSK: Geographical segmentation of Ventolin 2015
  • Exhibit 56: Teva Pharmaceutical: Profile
  • Exhibit 57: Teva Pharmaceutical: Strength assessment
  • Exhibit 58: Teva Pharmaceutical strategy assessment
  • Exhibit 59: Teva Pharmaceutical: Opportunity assessment
  • Exhibit 60: Teva Pharmaceuticals: YoY revenue and growth rate of ProAir 2013-2015 ($ millions)
Back to Top
전화 문의
F A Q